Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday before market open. Here’s what to look for.
Incyte beat analysts’ revenue expectations by 8.4% last quarter, reporting revenues of $1.37 billion, up 20% year on year. It was an incredible quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.
Is Incyte a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Incyte’s revenue to grow 14.8% year on year to $1.35 billion, slowing from the 16.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.95 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Incyte has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.4% on average.
Looking at Incyte’s peers in the biotechnology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Regeneron delivered year-on-year revenue growth of 2.5%, beating analysts’ expectations by 2.7%, and Biogen reported a revenue decline of 7.1%, topping estimates by 3.6%. Regeneron’s stock price was unchanged following the results.
Read our full analysis of Regeneron’s results here and Biogen’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Incyte is up 1.9% during the same time and is heading into earnings with an average analyst price target of $104.23 (compared to the current share price of $108.37).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.